Nqo1 ablation inhibits activation of the PI3K/Akt and MAPK/ERK pathways and blocks metabolic adaptation in hepatocellular carcinoma

• Published in: Hepatology (Baltimore, Md.) Vol. 71; no. 2; pp. 549 - 568
• Main Authors: Dimri, Manali, Humphries, Ashley, Laknaur, Archana, Elattar, Sawsan, Lee, Tae Jin, Sharma, Ashok, Kolhe, Ravindra, Satyanarayana, Ande
• Format: Journal Article
• Language: English
• Published: 19.08.2019
• ISSN: 0270-9139; 1527-3350
• DOI: 10.1002/hep.30818

Cancer cells undergo metabolic adaptation to sustain uncontrolled proliferation. Aerobic glycolysis and glutaminolysis are two of the most essential characteristics of cancer metabolic reprogramming. Hyper-activated PI3K/Akt and MAPK/ERK signaling pathways play central roles in cancer cell metabolic adaptation since their downstream effectors, such as Akt and c-Myc, control most of the glycolytic and glutaminolysis genes. Here, we report that the cytosolic flavoprotein Nqo1 is strongly overexpressed in mouse and human hepatocellular carcinoma (HCC). Knockdown of Nqo1 enhanced activity of the serine/threonine phosphatase PP2A, which operates at the intersection of the PI3K/Akt and MAPK/ERK pathways and dephosphorylates and inactivates PDK1, Akt, Raf, MEK and ERK1/2. Nqo1 ablation also induced the expression of PTEN, a dual protein/lipid phosphatase that blocks PI3K/Akt signaling, via the ERK/CREB/c-Jun pathway. Together, Nqo1 ablation triggered simultaneous inhibition of the PI3K/Akt and MAPK/ERK pathways, suppressed the expression of glycolysis and glutaminolysis genes and blocked metabolic adaptation in liver cancer cells. Conversely, Nqo1 overexpression caused hyper-activation of the PI3K/Akt and MAPK/ERK pathways and promoted metabolic adaptation. In conclusion , Nqo1 functions as an upstream activator of both the PI3K/Akt and MAPK/ERK pathways in liver cancer cells, and Nqo1 ablation blocked metabolic adaptation and inhibited liver cancer cell proliferation and HCC growth in mice. Therefore, our results suggest that Nqo1 may function as a therapeutic target to inhibit liver cancer cell proliferation and inhibit HCC.